Takeda buys Seattle startup PvP Biologics for up to $330M, will advance TAK-062 into Phase 2

Japanese pharmaceutical Takeda acquired Seattle biotech PvP Biologics for up to $330 million in late February, taking over its TAK-062 (Kuma062) program and all clinical and manufacturing activities while laying off PvP staff. Takeda plans to run phase 2 trials of the enzyme-based celiac disease treatment that PvP developed after earlier funding of $35 million supported phase 1 work.

DDavid Baker IIngrid Swanson Pultz UUniversity of Washington